Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Abstract Background Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect evidence of some aspects of the safety and...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martínez
বিন্যাস: প্রবন্ধ
ভাষা:English
প্রকাশিত: BMC 2023-09-01
মালা:Annals of General Psychiatry
বিষয়গুলি:
Schizophrenia
Risperidone
Matching-adjusted indirect comparison
MAIC
Extrapyramidal symptom
Anticholinergics
অনলাইন ব্যবহার করুন:https://doi.org/10.1186/s12991-023-00464-z

আন্তর্জাল

https://doi.org/10.1186/s12991-023-00464-z

অনুরূপ উপাদানগুলি